Synosia Therapeutics Announces Appointment of Vice President of Clinical Research and Development



    SAN FRANCISCO, CA, Nov. 5 /CNW/ - Synosia Therapeutics today announced
the appointment of Uwe Meya, M.D., as the company's new vice president of
clinical research and development, effective immediately.
    Dr Meya, who joins Synosia's Basel operation, is a neurologist and
psychiatrist by training with an impressive track record of more than 20 years
in pharmaceutical research and development, focused on disorders of the
central nervous system (CNS). His experience spans multiple CNS indications
and covers the full spectrum of drug development from first-in-man through to
regulatory filing.
    At Novartis, Meya managed a team of researchers in CNS clinical
development and was a member of a special CNS clinical development management
team, overseeing projects from late pre-clinical studies through to the end of
Phase I.
    Most recently he was at Roche as head of research portfolio management in
Basel, where he contributed to the global strategic direction of all
therapeutic areas. Meya also served at Roche as clinical research and
licensing liaison manager in CNS and received the Roche Global Development
Leadership Reward in recognition of his effectiveness in building
relationships and partnerships.
    While at Roche and Novartis, Meya worked on several of the compounds
subsequently out-licensed to Synosia.
    "Uwe Meya brings a depth of experience in neurology and psychiatry that
enhances our already solid capabilities in those areas," said Synosia Chief
Executive Officer and President Ian Massey, "and his recognized effectiveness
in building business relationships can only help us as we work with our
current partners at Novartis, Roche and Syngenta and eventually look for
partners to commercialize products for larger markets."
    "It's an exciting time to be joining Synosia with four compounds entering
phase 2 studies in 2008 and another preparing to enter a proof-of-concept
study," said Meya. "I've felt that CNS is ready for a new approach in
development, and I appreciate Synosia's method of using smart, efficient
proof-of-concept studies to gain predictive data moving into full phase 2
trials."
    Meya was educated in Germany and studied medicine in Aachen, Germany and
in Glasgow, Scotland. He received his medical degree from the University of
Aachen, where he also completed a doctorate in psychiatry, before undertaking
clinical service to become a board-qualified neurologist and psychiatrist.
    He is a member of the European College of Neuropsychopharmacology and is
a founding member of the International College of Geriatric
Psychoneuropharmacology, where he served as a council member for more than
three years.

    About Synosia Therapeutics

    Synosia Therapeutics develops and intends to commercialize innovative and
clinically differentiated products for unmet medical needs in psychiatry and
neurology. The privately-owned company is developing six clinical-stage
compounds acquired through key partnerships with Novartis, Roche and Syngenta,
 including two marketed drugs that will be tested in new indications,
extending their reach into new therapeutic areas with combined sales potential
in excess of US$2.5 billion. Synosia has offices in Basel, Switzerland, and
South San Francisco, CA.
    Synosia Therapeutics has raised US$32.5 million funding from Versant
Ventures (Menlo Park, CA), Abingworth Management (London), 5AM Ventures (Menlo
Park, CA) and Novo A/S (Copenhagen, Denmark). For more information, visit
http://www.synosia.com.





For further information:

For further information: Media Release: Contact Synosia Therapeutics, In
Europe, Julie Walters at Media Speak, Tel: +44(0)149-475-3990, Mobile
+44(0)775-362-6967, julie.walters@mediaspeak.com; In US, Michele Parisi at
Media Speak, Tel: (925) 864-5028, michele.parisi@mediaspeak.com

Organization Profile

SYNOSIA THERAPEUTICS

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890